The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of vaso-occlusive crises (VOCs).

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Q4 2024 Earnings Call Transcript March 11, 2025 MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.1004, ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

The stock, which has tumbled more than 45% over the past year, could climb 87% within the coming 12 months, Wall Street ...

With its flagship product Casgevy gaining traction and a diverse pipeline spanning multiple therapeutic areas, the company faces both significant opportunities and challenges in the rapidly ...

Vertex's products are known as cystic fibrosis transmembrane ... The company's blood disorders treatment -- Casgevy -- also is a multibillion-dollar opportunity, according to Vertex.

With its flagship product Casgevy gaining traction and a diverse pipeline spanning multiple therapeutic areas, the company faces both significant opportunities and challenges in the rapidly evolving ...

New patient starts are expected to grow significantly throughout 2025. During its fourth-quarter earnings release on Monday, Vertex recorded $8 million in product revenues from Casgevy sales.

The company made a major breakthrough in late 2023 when its first product, CASGEVY, became the first-ever CRISPR-based therapy to gain FDA approval. CASGEVY targets two blood disorders—sickle ...